These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 18483317)
1. PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Madhunapantula SV; Desai D; Sharma A; Huh SJ; Amin S; Robertson GP Mol Cancer Ther; 2008 May; 7(5):1297-308. PubMed ID: 18483317 [TBL] [Abstract][Full Text] [Related]
2. Melanoma prevention using topical PBISe. Chung CY; Madhunapantula SV; Desai D; Amin S; Robertson GP Cancer Prev Res (Phila); 2011 Jun; 4(6):935-48. PubMed ID: 21367959 [TBL] [Abstract][Full Text] [Related]
3. The selenium analog of the chemopreventive compound S,S'-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea is a remarkable inducer of apoptosis and inhibitor of cell growth in human non-small cell lung cancer. Das A; Bortner J; Desai D; Amin S; El-Bayoumy K Chem Biol Interact; 2009 Jul; 180(2):158-64. PubMed ID: 19497413 [TBL] [Abstract][Full Text] [Related]
4. Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats. Janakiram NB; Mohammed A; Ravillah D; Choi CI; Zhang Y; Desai D; Amin S; Rao CV Oncol Rep; 2013 Aug; 30(2):952-60. PubMed ID: 23708609 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer. Desai D; Madhunapantula SV; Gowdahalli K; Sharma A; Chandagaludoreswamy R; El-Bayoumy K; Robertson GP; Amin S Bioorg Med Chem Lett; 2010 Mar; 20(6):2038-43. PubMed ID: 20153642 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Gowda R; Madhunapantula SV; Desai D; Amin S; Robertson GP Mol Cancer Ther; 2013 Jan; 12(1):3-15. PubMed ID: 23112250 [TBL] [Abstract][Full Text] [Related]
7. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Sharma A; Sharma AK; Madhunapantula SV; Desai D; Huh SJ; Mosca P; Amin S; Robertson GP Clin Cancer Res; 2009 Mar; 15(5):1674-85. PubMed ID: 19208796 [TBL] [Abstract][Full Text] [Related]
8. A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer. Tagaram HR; Desai D; Li G; Liu D; Rountree CB; Gowda K; Berg A; Amin S; Staveley-O'Carroll KF; Kimchi ET Pharmaceuticals (Basel); 2016 Mar; 9(2):. PubMed ID: 27023566 [TBL] [Abstract][Full Text] [Related]
10. Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis. Chen T; Nines RG; Peschke SM; Kresty LA; Stoner GD Cancer Res; 2004 May; 64(10):3714-7. PubMed ID: 15150132 [TBL] [Abstract][Full Text] [Related]
11. PRAS40 deregulates apoptosis in malignant melanoma. Madhunapantula SV; Sharma A; Robertson GP Cancer Res; 2007 Apr; 67(8):3626-36. PubMed ID: 17440074 [TBL] [Abstract][Full Text] [Related]
12. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Jiang C; Wang Z; Ganther H; Lü J Mol Cancer Ther; 2002 Oct; 1(12):1059-66. PubMed ID: 12481429 [TBL] [Abstract][Full Text] [Related]
13. Novel seleno- and thio-urea derivatives with potent in vitro activities against several cancer cell lines. Alcolea V; Plano D; Karelia DN; Palop JA; Amin S; Sanmartín C; Sharma AK Eur J Med Chem; 2016 May; 113():134-44. PubMed ID: 26922233 [TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways. Pisano M; Arru C; Serra M; Galleri G; Sanna D; Garribba E; Palmieri G; Rozzo C Metallomics; 2019 Oct; 11(10):1687-1699. PubMed ID: 31490510 [TBL] [Abstract][Full Text] [Related]
16. Searching for the Achilles' heel of melanoma cells: new treatment modalities. Melnikova VO; Bar-Eli M Pigment Cell Melanoma Res; 2008 Oct; 21(5):505-6. PubMed ID: 18713130 [No Abstract] [Full Text] [Related]
17. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. Albino AP; Juan G; Traganos F; Reinhart L; Connolly J; Rose DP; Darzynkiewicz Z Cancer Res; 2000 Aug; 60(15):4139-45. PubMed ID: 10945621 [TBL] [Abstract][Full Text] [Related]
18. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667 [TBL] [Abstract][Full Text] [Related]
19. Targeting multiple key signaling pathways in melanoma using leelamine. Gowda R; Madhunapantula SV; Kuzu OF; Sharma A; Robertson GP Mol Cancer Ther; 2014 Jul; 13(7):1679-89. PubMed ID: 24688050 [TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]